Metrics as of 10/16/2026, 08:31 AM (Berlin time), refresh in progress.
Maze Therapeutics Stock
Maze Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jason Coloma
- Employees
- 141
- Market cap
- $1.5 B
- IPO
- 31/01/2025
Maze Therapeutics, Inc. is a clinical stage biopharmaceutical company headquartered in South San Francisco, USA. Founded in 2017, the company focuses on developing small molecule precision medicines for the treatment of kidney and metabolic diseases. Its lead programs include MZE829, an oral small molecule inhibitor…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Maze Therapeutics stock: price history
1D
+4.8%
1W
+6.2%
1M
+13.4%
6M
+2.3%
YTD
-33.7%
1Y
-6.1%
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~41% stronger price swings than usual
Ask the agents about Maze Therapeutics
Analyst assessment of Maze Therapeutics
PRICE TARGET LOW
US$17.00
CONSENSUS
US$54.13
MEDIAN
US$51.50
PRICE TARGET HIGH
US$97.00
0
STRONG BUY
6
BUY
0
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 24/09/2026
Maze Therapeutics stock metrics
P/E
-10.03
P/B
3.58
EV/EBITDA
-10.66
RETURN ON EQUITY
-9.9%
NET MARGIN
0.0%
DEBT/EQUITY
0.13
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
28.9%
FLOAT SHARES
16,037,544
AVG. DAILY VOLUME (30D)
841,667
Insider transactions (SEC)
Coloma Jason V
Coloma Jason V
Bernstein Harold
Bernstein Harold
Dandekar Atul
Institutional holders
Comparable stocks
Frequently asked questions about Maze Therapeutics stock
What does Maze Therapeutics do?
Maze Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jason Coloma, the company employs around 141 people.
The IPO was on 31/01/2025; the stock trades on NASDAQ under the ticker MAZE.
What do analysts say about Maze Therapeutics stock?
6 analysts rate the stock, the consensus is Buy (as of 24/09/2026).
The average price target is US$54.13, ranging from US$17.00 to US$97.00, with a median of US$51.50.
This is an external assessment, not a statement by Market Jury.
When does Maze Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 41% stronger than usual.
Does Maze Therapeutics pay a dividend?
No, Maze Therapeutics currently does not pay a dividend.
Which stocks are comparable to Maze Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Maze Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Maze Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.